Intelligence Feed event · Equity · 2026-09-12

    Eli Lilly posts $2.6B in H1 immunology revenue, up 9% YoY

    Question

    Eli Lilly posts $2.6B in H1 immunology revenue, up 9% YoY

    Direct answer

    Eli Lilly disclosed H1 2026 immunology revenue of $2.6 billion, representing a 9% year-over-year increase and accounting for 6.1% of top-line revenue. While GLP-1 metabolic treatments dominate Lilly's recent growth, newer immunology drugs including Ebglyss and Omvoh, alongside acquired pipelines from DICE, Morphic, and Merida, are expanding non-metabolic cash flows.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-12
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Eli Lilly posts $2.6B in H1 immunology revenue, up 9% YoY”, revision 1, evidence through 2026-09-12. https://marketontology.com/market-events/2026-09-12/eli-lilly-posts-2-6b-in-h1-immunology-revenue-up-9-yoy-9416ab

    EQUITY
    Eli Lilly posts $2.6B in H1 immunology revenue, up 9% YoY
    Eli Lilly disclosed H1 2026 immunology revenue of $2.6 billion, representing a 9% year-over-year increase and accounting for 6.1% of top-line revenue. While GLP-1 metabolic treatments dominate Lilly's recent growth, newer immunology drugs including Ebglyss and Omvoh, alongside acquired pipelines from DICE, Morphic, and Merida, are expanding non-metabolic cash flows.
    LLY
    Impact
    66
    SEP 12
    SIG
    88%
    LLY
    Eli Lilly posts $2.6B in H1 immunology revenue, up 9% YoY
    Eli Lilly disclosed H1 2026 immunology revenue of $2.6 billion, representing a 9% year-over-year increase and accounting for 6.1% of top-line revenue. While GLP-1 metabolic treatments dominate Lilly's recent growth, newer immunology drugs including Ebglyss and Omvoh, alongside acquired pipelines from DICE, Morphic, and Merida, are expanding non-metabolic cash flows.
    → Broadening revenue diversification into immunology through Ebglyss and Omvoh cushions Lilly's gross cash flow profile against potential GLP-1 pricing and capacity cycles.
    Impact
    Eli Lilly disclosed H1 2026 immunology revenue of $2.6 billion, representing a 9% year-over-year increase and accounting for 6.1% of top-line revenue. While GLP-1 metabolic treatments dominate Lilly's recent growth, newer immunology drugs including Ebglyss and Omvoh, alongside acquired pipelines from DICE, Morphic, and Merida, are expanding non-metabolic cash flows.
    Affected
    LLY
    Transmission
    Broadening revenue diversification into immunology through Ebglyss and Omvoh cushions Lilly's gross cash flow profile against potential GLP-1 pricing and capacity cycles.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYtherapeutic pipeline diversification into high-margin immunology franchisesUp1-3mH1 immunology revenue reached $2.6B (+9% YoY) with launches of Ebglyss and Omvoh.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month